Revenue
2019
2020
2021
2022
2023
2024
2025
Lyell Immunopharma, Inc. (LYEL)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $36,000 | $61,000 | $130,000 | $84.7M | $10.7M | $7.8M | $657,000 |
| Research & development | $158.7M | $171.6M | $182.9M | $159.2M | $138.7M | $182.2M | $63.6M |
| Operating expenses | $269.4M | $358.8M | $247.1M | $271.7M | $225.4M | $219.7M | $102.7M |
| Operating income | −$269.4M | −$358.8M | −$247.0M | −$187.1M | −$214.8M | −$211.9M | −$102.1M |
| EBITDAderived | −$257.9M | −$339.1M | −$226.8M | −$169.0M | −$201.2M | −$207.6M | −$100.8M |
| Net income | −$274.4M | −$343.0M | −$234.6M | −$183.1M | −$250.2M | −$204.5M | −$129.4M |
| Basic EPSper diluted share | -$16.06 | -$26.23 | -$18.70 | -$0.74 | -$1.84 | -$15.69 | -$24.04 |
| Diluted EPSper diluted share | -$16.06 | -$26.23 | -$18.70 | -$0.74 | -$1.84 | -$15.69 | -$24.04 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 10, 2026Form 4 | Shook DavidChief Medical Officer | SellCommon Stock | 2.0K | $12.64 | $25.0K | 20.9K |
| May 11, 2026Form 4 | Bulis Veronica SanchezVP, Corporate Controller | SellCommon Stock | 217 | $18.91 | $4.1K | 15.4K |
| May 11, 2026Form 4 | Lee Gary K.Chief Scientific Officer | SellCommon Stock | 130 | $18.92 | $2.5K | 17.8K |
| May 11, 2026Form 4 | Hill Stephen J.Chief Operating Officer | SellCommon Stock | 89 | $18.92 | $1.7K | 17.9K |
| May 11, 2026Form 4 | Seely LynnPresident and CEO | SellCommon Stock | 388 | $18.91 | $7.3K | 73.9K |